appConfigEntityId

bodyType

customContents

entityId

entityUuid

isVideo

articlePageQuery

article

articleSchemaContent

content

hooksArticlePageAdvertisementConfigArticle

hooksArticlePageFloatingButtonConfigArticle

appConfig

filter

json

liveArticle

Julie Zhang

Clinical drug trial registrations in China hit a record last year, the country’s drug regulator said, with more than 5,000 trials reported in the latest sign of the nation’s growing pipeline of novel drug candidates.
The total number of clinical drug trials reached 5,215 in 2025, more than double the figure recorded in 2020, according to a report released by the National Medical Products Administration on Monday.
Of those, 57.5 per cent were trials for new drugs, an 18 per cent year-on-year increase, while the remainder were bioequivalence studies, which test whether a generic drug performs identically to its branded counterpart in the body.
Trials were concentrated in Beijing and Shanghai, as well as in the provinces of Guangdong and Jiangsu, the report said.
Chinese companies and institutions initiated or funded 93 per cent of all registered trials. About 92 per cent were conducted within China, while the rest were part of global studies that included patient sites in the country.
Cancer treatments remained the most common focus of the new drug trials, followed by medicines for skin, eye, ear and throat conditions, drugs targeting hormonal and metabolic disorders such as diabetes and thyroid disease, and vaccines designed to prevent infectious diseases, the report showed.
Traditional Chinese medicine trials focused on respiratory conditions and mental and neurological disorders.
The record-breaking figures come as Beijing doubles down on advancing biotechnology as a strategic industry to help drive economic growth. Chinese drug makers have increasingly moved up the global pharmaceutical value chain, with a growing number of home-grown drugs finding their way into overseas markets.
Data presented at the Outsourcing in Clinical Trials industry conference, held in California in February, showed clinical trials in China cost 50 to 60 per cent less than in the United States, and are completed more quickly.
Meanwhile, China’s growing significance in biotech has drawn the attention of officials in Washington. On June 2, US lawmakers introduced the Biotech Investment National Security Act, or BINSA, a bill that would subject American licensing deals, joint ventures and equity investments in Chinese biotech companies to a national security review by the US Treasury Department.
“The news may continue to weigh on China biotech firms”, though a full decoupling from the Chinese sector is impossible, said Tony Ren, head of Asia healthcare research at Macquarie Capital.
Ren said BINSA had triggered a “derating” of biotech stocks, pushing the valuation multiple that investors are willing to pay for every dollar of future earnings down to around 22 times, but added that he saw “limited further downside risk” from current levels.


China cracks down on big firms delaying payments to cash-strapped SMEs

Veteran investor Fang Fenglei on why the China ‘investibility’ debate is no debate at all

Why Chinese shoppers are ditching supermarkets for small ‘community stores’

Mainland Chinese shoppers lose trusted Hong Kong veggie tag as customs revamp hits shelves

China’s private sector

China’s biotech surge sparks US security concerns as drug trials break records in 2025

Cancer research being conducted in a modern lab. Cancer treatments remained the top focus of the record 5,215 clinical drug trials in China last year. Photo: Shutterstock

Cross-border biotech deals grow more complex as US targets China investment links

In focus: Chinese biotech firms such as Jiangsu Hengrui Pharmaceutical are navigating growing geopolitical scrutiny as cross-border licensing deals continue to expand. Photo: Shutterstoc

A pharmaceutical production line manufacturing capsules. China has become a major source of drug candidates for multinational pharmaceutical companies seeking new treatments. Photo: Shutterstock

China’s biotech industry sees global expansion as unstoppable, despite US pressure

Chinese companies now account for about half of all global biotechnology business development deals. Photo: Shutterstock

The geopolitical headwinds facing China’s biotech sector are showing little sign of easing. Photo: Shutterstock

Chinese pharmaceutical firms’ cost advantages trump Pentagon blacklist: analysts

The cost advantages of Chinese pharmaceuticals mean they still appeal to multinational drug makers despite US security concerns. Photo: TNS

Which company could become the Chinese Pfizer? Here are analysts’ top picks

Chinese pharmaceutical companies may expand into international markets in the coming years. Photo: Shutterstock

A Hansoh Pharmaceutical research centre in Lianyungang, a city in China’s eastern Jiangsu province.. Photo: Handout

An employee at the Hengrui Biomedical Industrial Park in Lianyungang, in China’s eastern Jiangsu province. Photo: Getty Images

US President Donald Trump on stage with Health and Human Services Secretary Robert F. Kennedy Jnr before he speaks about prescription drug prices at the White House on May 18. Photo: AP

Targeting US$610 billion longevity market, biotech firms race to reverse ageing

Illustration: Lau Ka-kuen

Business

China Business

Companies

Markets

Money

Markets & Investing

Cancer treatments remain the top research focus as Beijing’s drive to make biotech a strategic industry draws attention in Washington


Cancer treatments remain the top research focus as Beijing’s drive to make biotech a strategic industry draws attention in Washington.


China’s biotech surge sparks US security concerns as drug trials break records in 2025

.css-1c6uqr6{color:inherit;font-weight:inherit;font-size:inherit;font-family:inherit;line-height:inherit;overflow-wrap:break-word;}Cancer treatments remain the top research focus as Beijing’s drive to make biotech a strategic industry draws attention in Washington

Cancer treatments remain the top research focus as Beijing’s drive to make biotech a strategic industry draws attention in Washington